| R. Terry Bartus | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Southern California Ceregene (Founder) |
| Country | USA |
| H-index | 150 |
| ORCID | 0000-0003-2927-6570 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Cholinergic, Neurotrophic factors, Gene Therapy |
R. Terry Bartus is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
R. Terry Bartus is a renowned neuroscientist and pharmaceutical executive who has made pioneering contributions to Alzheimer's disease research. He is affiliated with the University of Southern California and is the founder of Ceregene, a biotechnology company focused on gene therapy for neurodegenerative diseases. With an h-index of 150, Bartus is among the most influential figures in translational neuroscience and drug development for Alzheimer's disease.
Bartus's research career spans over four decades, with groundbreaking contributions to understanding the cholinergic system in memory function, pioneering work in neurotrophic factor therapy, and innovative approaches to gene therapy for brain disorders. His work has directly contributed to the development of several therapeutic strategies currently in clinical use or development for Alzheimer's disease.
Bartus conducted foundational research on the cholinergic system's role in memory and cognitive function[1]. His work demonstrated that degeneration of cholinergic ](/entities/neurons) in the basal forebrain contributes to memory deficits in Alzheimer's disease, establishing the rationale for cholinergic replacement therapies. This research helped pioneer the development of acetylcholinesterase inhibitors, which remain a standard treatment for Alzheimer's disease symptoms.
A significant portion of Bartus's career has been devoted to developing neurotrophic factor therapies for neurodegenerative diseases[2]. He demonstrated that delivery of nerve growth factor (NGF) to the basal forebrain could protect cholinergic neurons from degeneration. This work represented a novel disease-modifying approach rather than merely symptomatic treatment.
Bartus pioneered the use of adeno-associated virus (AAV) vectors for delivering therapeutic genes to the brain[3]. His work at Ceregene focused on gene therapy approaches to deliver neurotrophic factors directly to affected brain regions, establishing important safety and efficacy benchmarks for CNS gene therapy.
As founder and former CEO of Ceregene, Bartus led the development of gene therapy products for Alzheimer's and Parkinson's diseases. The company's lead candidate, CERE-110 (AAV-NGF), underwent clinical testing for Alzheimer's disease, representing one of the first gene therapy approaches to reach clinical trials for a neurodegenerative disease.
Bartus has contributed to the development of multiple therapeutic candidates that have advanced to clinical trials, including both small molecule agents and biological therapeutics. His expertise spans the entire drug development pipeline from target identification through clinical trials.
The study of R. Terry Bartus has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
R. Terry Bartus is a renowned neuroscientist and pharmaceutical executive who has made significant contributions to Alzheimer's disease research, particularly in the areas of cholinergic neurotransmission and neurotrophic factors. His work has advanced understanding of memory deficits in aging and neurodegenerative diseases.
Bartus co-founded Ceregene, a biotechnology company focused on gene therapy for neurodegenerative diseases. His laboratory developed innovative approaches for delivering therapeutic proteins across the blood-brain barrier, advancing the field of neurotrophic factor therapy for Alzheimer's disease. He has served as principal investigator on numerous NIH-funded grants and has mentored dozens of students and postdoctoral fellows who have gone on to successful careers in neuroscience research.
His current work focuses on optimizing AAV vector designs for efficient gene delivery to the central nervous system and developing combination therapies that target multiple pathological mechanisms simultaneously.
Dr. Bartus has authored over 200 publications, including key papers on:
His work pioneered the use of neurotrophic factors for treating neurodegenerative disorders.
Dr. Bartus's research has advanced clinical neurology through:
Dr. Bartus has received multiple awards for his pioneering work in gene therapy and has founded biotechnology companies to translate his discoveries into treatments.